"I'm delighted to welcome Anne Marie Cook to Phathom. Her experience and broad skills will be highly impactful as we work to build Phathom into a leading GI company in the coming years,” said Steven ...

After the FDA rejection of Zurzuvae in one type of depression, and the triple failure of neuro asset dalzanemdor, Sage was ...

Biogen Inc. closed 46.93% short of its 52-week high of $238.00, which the company achieved on July 12th.

Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best ...

Logo TV, the first 24-hour LGBTQIA+ television network, launched June 30, 2005. Logo's first president reflects on its ...

Company News Published 06/18/2025, 07:35 AM 0 Biogen initiates phase 3 trial of omaveloxolone for children with FA BIIB -0.66% ...

TORONTO, June 5, 2025 /CNW/ - Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with ...

Revenue Growth: Biogen's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 6.13%.

A February conference by the drug company Biogen was initially thought to have infected 99 people. By the end of October, it was feared that the number had grown as high as 300,000.

Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced ...